Catalio Leads $40M Series B for Microbiome Startup Evvy
Fundraise Insider tracks newly funded startups each week and delivers verified sales leads of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.
Evvy has raised an oversubscribed $40 million Series B led by Catalio Capital Management. Rethink Impact, Muse Capital, Alumni Ventures, the LabCorp Venture Fund, and General Catalyst also took part.
The New York company launched in 2021 and is best known for what it describes as the world’s only at-home CLIA-certified and CLEP-certified mNGS test analyzing vaginal microbes from a single swab. Priyanka Jain, Laine Bruzek, and Pita Navarro founded it.
The flow is straightforward. A user mails a swab sample to Evvy’s lab, which runs its own mNGS sequencing, sends the results to clinicians registered on the platform for review, and posts them in the patient’s health portal alongside a diagnosis, clinical interpretation, and next steps, including prescription care where relevant.
Evvy now serves more than 100,000 patients across the United States and works with 3,000 practitioners. It has generated 15 peer-reviewed publications and abstracts, identified novel bacterial vaginosis subtypes, and catalogued hundreds of previously unrecorded vaginal microbiome genomes.
Treatment is only half the plan. The larger goal is a dataset connecting microbiome biology, symptoms, interventions, and health outcomes, feeding a loop that improves care and surfaces new biomarkers. Precision medicine for women runs into a basic obstacle here: the underlying datasets never adequately measured female biology to begin with, and leading AI models still struggle with questions about women’s health.
In May the company launched EvvyAI, an assistant that turns collected microbiome data into real-time guidance and routes patients to clinicians when a question needs expert judgment.
Fertility is the company’s first major move beyond vaginal health. It is compiling data linking vaginal microbiomes to infertility, gynecological cancer, preterm birth, IVF success rates, and recurrent pregnancy loss, and last year started a prospective study running its tests in IVF clinics. Other companies working in this space include Juno Bio, Tiny Health, and Daye.
Suppliers and service firms selling into newly funded healthcare companies can get verified contacts every week through Healthcare Sales Leads.